Revised SPC: Erythromycin ethyl succinate 250 mg/5 ml Granules for Oral Suspension

SPC updated with addition of a contraindication with lomitapide due to markedly increased transaminase levels with concomitant use, a warning to use with caution with corticosteroids and information on risk of congenital malformations after use during pregnancy.

SPS commentary:

The changes follow recommendations from the EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

Source:

electronic Medicines compendium

Resource links:

PRAC Meeting Minutes